Effective Monotherapy

Significantly lowers 3 major glycemic markers (p<0.05).^1,2

Reduces PPF and Reduces FPG

Provides the PROVEN EFFICANCY of Sulfonylureas

Reaching PPG goals is recommended

AACE/ACE‡ Consensus Conference Guidelines emphasize establishing PPG goals for patients with type 2 diabetes (<140 mg/dL)⁶

In clinical trials, the most common adverse events leading to discontinuation of Prandin^® therapy were hyperglycemia, hypoglycemia and related symptoms. The most common other side effects reported were cold- and flu-like symptoms, headache, diarrhea, joint ache and back pain.

* A 3-month, multicenter, randomized, double-blind, placebo-controlled, dose-titration study in patients with type 2 diabetes, with weekly increments of 0.25 mg, 0.5 mg, 1 mg, and 2 mg, up to a maximum dose of 4 mg preprandially or until FPG <160 mg/dL was achieved (PRANDIN^®, n = 66; placebo, n = 33).¹

†Madsbad, et al.⁴

‡The American College of Endocrinology (ACE) is the educational and research arm of the American Association of Clinical Endocrinologists (AACE).

References:

Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care. 1998;21:1897-1903.
PRANDIN^® Prescribing Information, Novo Nordisk Pharmaceuticals, Inc.
Madsbad S, Kilhovd B, Lager I, Mustajoki, Dejgaard A. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a one-year multicentre study. Diabetic Med. 2001; 18:395-401.
Marbury T, Huang W-C, Strange P, Lebovitz H. Repaglinide vs. glyburide: a one-year comparison trial. Diabetes Res Clin Pract. 1999;43:155-166.
The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management — 2002 Update. Developed by the American Association of Clinical Endocrinologists and the American College of Endocrinology — 2002. Endocrine Practice. 2002;8(January/February Suppl. 1):40-82.